Furthermore, in patients with refractory RA who received anti-tumor necrosis factor (TNF) therapy, sRANKL serum concentrations of RANKL have been suggested as potential predictive markers of remission [33]. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.